ADMA Biologics (ADMA) Linkedin Employees Statistics 2024

390

1M 2.6% 3M 10.8%

Employees on LinkedIn

Similar companies

Company		Linkedin Employees
	Amgen AMGN	35,747
	Gilead Sciences GILD	14,708
	Inovio Pharmaceuticals INO	217
	BridgeBio Pharma BBIO	683
	Crispr Therapeutics CRSP	437

Month over Month

Employees on LinkedIn

Oct 2024	380	2.4%
Sep 2024	371	5.4%
Aug 2024	352	2.6%
Jul 2024	343	0.6%
Jun 2024	341

How many employees work at ADMA Biologics?

ADMA Biologics has, according to their latest filings, 617 employees. 390 users on Linkedin state that they work for ADMA Biologics.

Analyzing Linkedin Employees, how is ADMA Biologics performing compared to its industry peers?

ADMA Biologics underperforms its industry peers when it comes to Linkedin Employees, ranking dead last.

How has the number of employees on LinkedIn for ADMA Biologics changed in the last month?

In the last month, there has been a positive increase in the number of employees at ADMA Biologics, with an addition of 2.6% employees. This could indicate growth and expansion within the company.

Why should investors track ADMA Biologics' employee count on LinkedIn?

Tracking ADMA Biologics' employee count on LinkedIn offers investors insights into the company's growth, strategic direction, and operational health. An increasing count may indicate expansion and scaling, suggesting a positive business trajectory, while a decrease could signal downsizing or challenges. However, this data can be volatile. LinkedIn updates depend on individual employees, potentially delaying reflectance of actual changes. Not all employees use LinkedIn, possibly leading to underrepresentation, while outdated profiles might inflate figures. While useful for trends, it's crucial to cross-reference with official data for a comprehensive picture.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.